Precipio, Inc. annual report, FY2014

Business context and reporting period

This is Transgenomic, Inc.’s Form 10-K for the fiscal year ended December 31, 2014, filed April 15, 2015. The request identifies Precipio, Inc., but the supplied filing is for Transgenomic; confirm the intended issuer. This is an annual report, not a standalone fourth-quarter filing, though unaudited quarterly data is included.

Transgenomic operated Laboratory Services and Genetic Assays and Platforms businesses. Its strategy centered on commercializing its high-sensitivity MX-ICP cancer-testing technology, primarily through licensing and partnerships.

Key financial metrics

Laboratory Services revenue rose 7% to $16.5 million, including 23% growth in patient testing; Genetic Assays and Platforms revenue fell 13% to $10.6 million. The 2014 net loss included a $4.1 million gain on the Surveyor product-line sale. Preferred-stock dividends and accretion were $1.1 million. Fourth-quarter sales were $7.7 million; patient-testing sales increased 90% year over year for that quarter.

Material changes versus the prior comparable period

• Sales declined 2%, while gross margin fell three percentage points. Management attributed pressure to weaker instrument and consumables sales and lower contract-laboratory activity, partly offset by patient-testing growth.
• Operating loss widened by $1.6 million, reflecting lower gross profit and slightly higher operating expenses. Net loss narrowed largely because of the Surveyor sale gain, rather than improved operating performance.
• Operating cash use increased to $13.7 million, including an $8.5 million increase in accounts receivable and a $6.1 million doubtful-account provision. The year-end allowance for doubtful accounts was $7.9 million.
• Year-end stockholders’ equity declined to $6.6 million from $11.4 million. The company raised capital through preferred stock and common-stock placements and issued convertible debt.

Outlook, risks and unusual items

• Management targeted an early-2015 commercial launch of MX-ICP and anticipated licensing or partnership transactions in 2015; the filing provides no quantified revenue or earnings guidance. The technology’s commercial adoption and clinical validation remained uncertain.
• Management said its operating plan relied on improving results and collections, monetizing underused assets and, if needed, obtaining further financing. The company and its auditor disclosed substantial doubt about its ability to continue as a going concern.
• After year-end, the company reported approximately $7.1 million in net proceeds from convertible notes and a common-stock offering. The February 2015 offering issued 3.6 million shares and warrants, creating potential dilution. The filing also describes subsequent amendments to lender terms.
• Debt included a $3.0 million revolving line and a $4.1 million term loan, secured by company assets and subject to financial covenants. The April 2015 amendment deferred term-loan principal payments until April 2016, while requiring interest payments and an initial prepayment.
• Management found material weaknesses in revenue-recognition controls and in controls over the doubtful-account allowance; disclosure controls were deemed ineffective at December 31, 2014. Management described remediation steps beginning in 2015. The weaknesses did not result in a reported restatement. The financial-statement audit opinion was unqualified but included a going-concern emphasis.
• Other notable items include the Surveyor sale for an initial $3.65 million plus scheduled payments and a possible earn-out; $128.9 million of federal tax-loss carryforwards, substantially offset by a valuation allowance; and potential dilution from outstanding options, warrants, preferred stock and convertible notes.

Important facts for investors to verify

• Confirm issuer identity: the supplied 10-K is for Transgenomic, not Precipio.
• Check subsequent filings for MX-ICP launch progress, licensing agreements, validation results and realized commercial revenue.
• Review receivable aging, collection trends, bad-debt assumptions and whether the identified control weaknesses were remediated and tested.
• Assess cash runway, operating cash burn, debt-covenant compliance, lender amendments and availability of additional financing.
• Quantify dilution from post-year-end equity issuance, convertible notes, preferred stock and repriced warrants.